HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag045 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Giuseppe Lapadula und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Milano-Bicocca, Milan, Italy. Hauptthemen laut MEDLINE: Anti-HIV Agents, Drug Substitution, Hepatitis B, Chronic, HIV Infections. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has been associated with reduced transaminase level among people with HIV (PWH), with and without HBV. It is unclear whether the effect is mediated by HBV serostatus.
Methods
We conducted a longitudinal observational study of PWH who switched from TDF to TAF between 2016 and 2023. A mixed-effects model with random intercepts assessed the effect of the switch on transaminases, including an interaction term for HBV status: chronic hepatitis B (HBsAg+), possible occult HBV infection (pOBI; HBsAg−/HBcAb+) and no HBV.
Results
Among 727 individuals, 7% had chronic hepatitis B and 35% had pOBI. Switching to TAF was associated with a significant ALT decrease (β −3.5 UI/mL, 95%CI: −5.2 to −1.9). Compared to HBV-negative individuals, individuals with chronic hepatitis B experienced steeper ALT reduction (β −7.5, 95%CI: −11.8 to −3.2), while pOBI was associated with a non-significant reduction (β −1.9; 95%CI: −4.4–0.6; P = 0.133). These findings persisted after adjusting for other predictors of transaminase levels. TAF was also associated with accelerated weight gain (+0.75 kg/year, 95% CI: 0.63–0.87) and a transient drop in the Hepatic Steatosis Index (−0.22; 95% CI: −0.38 to −0.06) followed by an annual increase thereafter (+0.18/year; 95% CI: 0.10–0.27).
Conclusions
Switching from TDF to TAF is associated with modest but statistically significant ALT reduction in PWH, especially in HBsAg + individuals. Our findings suggest that TAF may represent a favourable option in this subgroup, although potential metabolic consequences warrant close monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Milano-Bicocca, Milan, Italy.
- Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori, Monza (MB), Italy.
- Bicocca Bioinformatics Biostatistics and Bioimaging Center - B4, University of Milano-Bicocca, Milan, Italy.
ORCID-Profile: Laura Antolini, Luca Mezzadri
Zitieren
APA
Lapadula, G., Soria, A., Antolini, L., Rugova, A., Colella, E., Sabbatini, F., Squillace, N., Mezzadri, L., Limonta, S., Cappelletti, A., Ranzani, A., & Bonfanti, P. (2026). HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag045
Vancouver
Lapadula G, Soria A, Antolini L, Rugova A, Colella E, Sabbatini F, et al. HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag045
BibTeX
@article{Lapadula2026,
author = {Lapadula, Giuseppe and Soria, Alessandro and Antolini, Laura and Rugova, Alban and Colella, Elisa and Sabbatini, Francesca and Squillace, Nicola and Mezzadri, Luca and Limonta, Silvia and Cappelletti, Anna and Ranzani, Alice and Bonfanti, Paolo},
title = {HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag045}
}
EUVIMED